A. Desrosières, Argument statistique. Pour une sociologie historique de la quantification (tome I), Gouverner par les nombres (tome II), 2008.

R. Diaze-bone and E. Didier, The Sociology of Quantification ? Perspectives on an Emerging Field in the Social Sciences, Historical Social Research, vol.41, issue.2, pp.7-26, 2016.

L. Doganova, Que vaut une molécule ? Formulation de la valeur dans les projets de développement de nouveaux médicaments. Revue d, Anthropologie des Connaissances, vol.9, issue.1, pp.17-38, 2015.

E. Dolgin, Big pharma moves from 'blockbusters' to 'niche busters', Nature Medicine, vol.12, issue.8, p.837, 2010.
DOI : 10.1038/nm0810-837a

M. F. Drummond, D. A. Wilson, P. Kanavos, P. Ubel, and J. Rovira, Assessing the economic challenges posed by orphan drugs, International Journal of Technology Assessment in Health Care, vol.22, issue.01, pp.36-42, 2007.
DOI : 10.1016/0168-8510(93)90042-N

I. Dussauge, C. Helgesson, and F. Lee, Value Practices in the Life Sciences and Medicine, 2015.
DOI : 10.1093/acprof:oso/9780199689583.001.0001

S. Epstein, Impure Science: AIDS, Activism, and the Politics of Knowledge, 1996.

C. Helgesson and F. Muniesa, For What It???s Worth: An Introduction to Valuation Studies, Valuation Studies, vol.1, issue.1, pp.1-10, 2013.
DOI : 10.3384/vs.2001-5992.13111

H. I. Hyry, A. D. Stern, T. M. Cox, and J. C. Roos, Limits on use of health economic assessments for rare diseases, QJM, vol.107, issue.3, pp.241-246, 2014.
DOI : 10.1093/qjmed/hcu016

M. Kornberger, L. Justesen, J. Mouritsen, and A. Madsen, Making Things Valuable, 2015.
DOI : 10.1093/acprof:oso/9780198712282.001.0001

W. H. Lyle, Letter: More on " orphan " drugs, New England Journal of Medicine, vol.292, issue.15, pp.813-814, 1975.

C. Mccabe, A. Tsuchiya, K. Claxton, and J. Raftery, Orphan drugs revisited, QJM, vol.99, issue.5, pp.341-346, 2006.
DOI : 10.1093/qjmed/hcl033

T. Moreira, The Transformation of Contemporary Healh Care: The Market, the Laboratory, and the Forum, 2012.

V. Rabeharisoa, M. Callon, M. Filipe, A. , A. Nunes et al., From ???politics of numbers??? to ???politics of singularisation???: Patients??? activism and engagement in research on rare diseases in France and Portugal, BioSocieties, vol.39, issue.5, pp.194-217, 2014.
DOI : 10.1007/978-94-009-3755-0_3
URL : https://hal.archives-ouvertes.fr/hal-00976580

V. Rabeharisoa, T. Moreira, and M. Akrich, Evidence-based activism: Patients???, users??? and activists??? groups in knowledge society, BioSocieties, vol.62, issue.3, pp.111-128, 2014.
DOI : 10.1515/9781400840397
URL : https://hal.archives-ouvertes.fr/hal-00976588

D. Tordrup, V. Tzouma, and P. Kanavos, Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Diseases and Orphan Drugs, An International Journal of Public Health, vol.1, issue.3, pp.86-97, 2014.